More stories

  • in

    Fox News names Jesse Watters as replacement for Tucker Carlson primetime slot

    Fox News said Jesse Watters would be its new 8 p.m. ET primetime host, replacing Tucker Carlson.
    The change comes after Tucker Carlson was ousted from the network following parent Fox Corp.’s $787.5 million settlement in Dominion Voting Systems’ defamation lawsuit.
    Since Carlson’s departure in April, there’s been a rotation of hosts in the primetime spot on Fox, and ratings have suffered.

    Jesse Watters host of “The Five” interviews Jenna Bush Hager and Barbara Bush during “The Five” at Fox News Studios on November 13, 2017 in New York City.
    John Lamparski | Getty Images

    Fox News has named Jesse Watters as the newest star of its 8 p.m. ET primetime slot, as the network looks to boost ratings two months after ousting Tucker Carlson from the post.
    Watters, who rose through the ranks from production assistant to one of the most popular faces on the network, has established himself as one of Fox News’ leading conservative voices. He is currently the host of the 7 p.m. opinion show “Jesse Watters Primetime,” and appears regularly on “The Five,” one of Fox News’ highest rated programs.

    As part of the nighty show shakeup, Laura Ingraham’s show will begin the primetime programming block at 7 p.m., while Sean Hannity’s segment will remain in the 9 p.m. slot. Greg Gutfield’s comedy program will move to 10 p.m.
    “FOX News Channel has been America’s destination for news and analysis for more than 21 years and we are thrilled to debut a new lineup,” said Fox News CEO Suzanne Scott in a news release. “The unique perspectives of Laura Ingraham, Jesse Watters, Sean Hannity, and Greg Gutfeld will ensure our viewers have access to unrivaled coverage from our best-in-class team for years to come.”
    The moves comes as Fox News’ primetime ratings have suffered since Carlson’s abrupt departure in April.
    The right wing host was ousted the week after parent company Fox Corp. agreed to shell out $787.5 million to settle Dominion Voting Systems’ defamation lawsuit. There was no sendoff for Carlson and his “Tucker Carlson Tonight,” which had long been one of Fox’s most-watched shows.
    Fox’s 8 p.m. ratings took a noticeable dip in the wake of Carlson’s departure, and fledgling networks like Newsmax reaped the benefits in the ensuing weeks.

    Carlson has since started his own show on Twitter. While Carlson has posted videos on Twitter, he has yet to publicly address why he was fired from Fox. His departure was reportedly the result of vulgar, behind-the-scenes messages unearthed during the discovery process in the Dominion lawsuit.
    Meanwhile, Fox News has since sent a cease-and-desist letter to Carlson, alleging a breach of contract by launching a new show on the social media platform, NBC News previously reported. More

  • in

    Novo Nordisk says high-dose experimental obesity pill leads to 15% weight loss

    Novo Nordisk’s high-dose experimental obesity pill helped overweight or obese adults lose around 15% of their body weight, according to new late-stage clinical trial results. 
    Novo Nordisk’s pill is an oral version of semaglutide, the active ingredient in the company’s blockbuster weight loss injections Ozempic and Wegovy.
    The new data comes as the Danish pharmaceutical company fights to maintain its dominant position in the booming weight loss drug market, which is seeing new competitors such as Pfizer and Eli Lilly emerge.

    Liselotte Sabroe | Afp | Getty Images

    Novo Nordisk’s high-dose experimental obesity pill helped overweight or obese adults lose around 15% of their body weight, according to new late-stage clinical trial results.
    The Danish company presented the data at a diabetes conference Sunday. Novo Nordisk told Reuters it plans to file for Food and Drug Administration approval of the drug later this year.

    Novo Nordisk is fighting to maintain its dominant position in the booming weight loss drug market as new competitors such as Eli Lilly and Pfizer develop their own effective treatments.
    Novo Nordisk’s pill is an oral version of semaglutide, the active ingredient in the company’s blockbuster weight loss injections Ozempic and Wegovy. Semaglutide mimics a hormone produced in the gut called GLP-1, which signals to the brain when a person is full. 
    Novo Nordisk already has an FDA-approved oral semaglutide, which is marketed under the brand name Rybelsus for the treatment of type 2 diabetes. But the highest dose of Rybelsus is 14 milligrams, while the company’s experimental obesity pill has a far larger dose of 50 milligrams. 
    The phase three trial followed 667 obese and overweight adults who did not have Type 2 diabetes.
    Patients who took 50 milligrams of the pill once a day for 68 weeks saw an average weight loss of 15.1%, when they used it alongside diet and physical activity, according to Novo Nordisk. That’s compared with a 2.4% weight loss for patients who took a placebo.

    Around 85% of patients who took the pill lost at least 5% of their body weight, while only 26% of those who received the placebo did. 
    The weight loss also led to “improvements in physical functioning, allowing participants to have an improved quality of life for everyday activities,” Dr. Filip Knop, an endocrinology professor at the University of Copenhagen who worked on the study, said in a statement. 
    The new data suggests that the high-dose pill may be as effective as Novo Nordisk’s weekly Wegovy injection, which also resulted in roughly 15% weight loss after 68 weeks. 
    But a pill would serve as a far more convenient way to treat obesity. 
    Knop said offering the pill to the public would “allow people who struggle to lose weight with diet and physical activity alone to take this effective medication in a way that best suits them.”
    Other companies are also developing oral weight loss treatments to appeal to those who don’t want weekly injections. 
    Overweight or obese patients who took Eli Lilly’s experimental pill orforglipron lost 14.7% of their body weight after 36 weeks, according to midstage clinical trial results the company released Friday. 
    Pfizer is also developing its own weight loss pill, called danuglipron, which patients take twice a day.
    But the pharmaceutical giant on Monday said it would stop developing its other experimental oral drug, lotiglipron, due to elevated liver enzymes in patients.
    Companies started focusing more on the weight loss industry after Novo Nordisk’s Ozempic and Wegovy catapulted to the national spotlight in recent years.  
    Social media influencers, Hollywood celebrities and even billionaire tech mogul Elon Musk have reportedly used the popular injections to get rid of unwanted weight. 
    That popularity sparked widespread shortages and an increase in cheaper knockoffs of the drugs. 
    Shortages and other factors such as high out-of-pocket costs without insurance or unpleasant side effects have forced some people to stop taking Ozempic or Wegovy. Many users have complained of a rebound in weight that’s difficult to control.
    More than two in five adults have obesity, according to the National Institutes of Health. About one in 11 adults have severe obesity. More

  • in

    Red Sox owners buy Boston team in Tiger Woods and Rory McIlroy’s golf league

    Red Sox owner Fenway Sports Group is buying the Boston team in a new golf league.
    TGL, developed by Tiger Woods and Rory McIlroy in partnership with the PGA Tour, will begin competition in January.
    The news comes as the PGA Tour and Saudi-backed LIV Golf hammer out a merger after a long, contentious legal fight.

    Another sports powerhouse has joined the ownership ranks of the golf league being developed by Tiger Woods and Rory McIlroy.
    Fenway Sports Group, owned and run by John Henry and Tom Werner, will be the second of six teams to join TGL, the primetime golf league set to begin competition in January.

    “We are excited for this new journey,” Henry and Werner said in an announcement Monday. “Through this new, tech-focused version of the game, New England sports fans will soon have a team of world-class PGA Tour players to cheer for and redefine for this community what it means to play the game in the modern era.”
    Fenway Sports Group owns several major sports franchises, including Major League Baseball’s Boston Red Sox, the Liverpool Football Club and the National Hockey League’s Pittsburgh Penguins. The FSG team is the second squad to be announced by TGL. On June 8, it announced that Reddit co-founder Alexis Ohanian, Serena Williams and Venus Williams became owners in a Los Angeles team.
    “The team at FSG is uniquely positioned to help build an expanding community for fans of golf and embracing that audience is foundational to the Boston’s TGL team’s mission,” said Mike McCarley, co-founder of TMRW Sports, which controls TGL.
    The development of TGL comes at a pivotal time for the big-money world of professional golf. Woods, McIlroy and McCarley founded TMRW Sports Group (pronounced “tomorrow”) last year in partnership with the PGA Tour. At the time, it was seen as a response to the Saudi-backed LIV Golf league, which was embroiled in a bitter legal fight with the PGA Tour.
    This month, however, the PGA Tour and LIV agreed to merge business interests to form a new company. McIlroy is one of the biggest public critics of LIV, and Woods reportedly rejected a massive offer to join the Saudi-funded league.

    Rory McIlroy shakes hands with Tiger Woods on the 18th green after they completed a practice round prior to the 2023 Masters Tournament at Augusta National Golf Club in Augusta, Georgia, April 3, 2023.
    Christian Petersen | Getty Images

    TGL will now try to capture a new, younger demographic using cutting-edge technology in primetime competitions that merge physical and virtual golf.
    The league will feature six teams, consisting of three PGA Tour players each, going head-to-head in match play in an arena in Palm Beach, Florida. The league has not yet announced a broadcast deal as it is in ongoing negotiations. That is expected to be finalized in the coming weeks, according to a source close to the matter.
    The star power of Woods and McIlroy has helped attract a handful of big names, including Justin Thomas, John Rahm, Collin Morikawa, Adam Scott, Justin Rose and Rickie Fowler.
    TGL hasn’t disclosed how much money it’s raised. Yet it has attracted many big name athletes as investors, including basketball greats Shaquille O’Neal, Stephen Curry and Kevin Durant; Formula 1 driver Lewis Hamilton; women’s soccer star Alex Morgan; and pro football’s Tony Romo and Josh Allen. Several professional sports team owners have invested, as well. More

  • in

    Pfizer to end development of experimental obesity pill due to elevated liver enzymes

    Pfizer said it would stop developing its experimental obesity and diabetes pill, lotiglipron, due to elevated liver enzymes in patients who took the drug in mid-stage clinical studies. 
    New York-based Pfizer said it will instead focus on its other oral obesity drug, danuglipron, which is in a fully enrolled phase two clinical trial. 
    Lotiglipron, danuglipron and Novo Nordisk’s blockbuster weight loss injections Ozempic and Wegovy are part of a class of drugs that’s piquing public interest.

    Pavlo Gonchar | Lightrocket | Getty Images

    Pfizer on Monday said it would stop developing its experimental obesity and diabetes pill, lotiglipron, due to elevated liver enzymes in patients who took the drug once a day in mid-stage clinical studies. 
    Those elevated enzymes often indicate damage to cells in the liver, but the pharmaceutical giant said no patients experienced liver-related symptoms or side effects. 

    Shares of Pfizer were down about 3.5% in premarket trading following the news.
    New York-based Pfizer said it will instead focus on its other oral obesity drug, danuglipron, which is in a fully enrolled phase two clinical trial. 
    That study found that body weight was reduced after patients with Type 2 diabetes took high-dose versions of danuglipron twice a day for 16 weeks, according to results Pfizer released last month.
    The company expects to finalize plans for phase three clinical trial program on danuglipron by the end of 2023. Pfizer added that it is also developing a version of danuglipron that patients take once a day instead of twice. 
    “We look forward to analyzing the danuglipron Phase 2 results and selecting the dose and titration schedule that will maximize the therapeutic benefit and safety and tolerability,” William Sessa, Pfizer’s chief scientific officer of internal medicine, said in a press release. 

    Lotiglipron, danuglipron and Novo Nordisk’s blockbuster weight loss injections Ozempic and Wegovy are part of a class of drugs called glucagon-like peptide-1 agonists.
    They mimic a hormone produced in the gut called GLP-1, which signals to the brain when a person is full. 
    The drugs can also help people manage Type 2 diabetes because they encourage insulin release from the pancreas, lowering blood sugar levels.
    Oral drugs like Pfizer’s danuglipron could offer an advantage over frequent injections. Novo Nordisk and Eli Lilly are also developing their own experimental obesity and diabetes pills.
    The new class of obesity drugs is piquing public interest and causing a weight loss industry gold rush. But there’s still uncertainty about their accessibility, and questions remain about how long patients would need to take the drugs to keep unwanted weight off.
    Some people who stop taking the drugs complain about a weight rebound that is difficult to control.
    More than 2 in 5 adults have obesity, according to the National Institutes of Health. About 1 in 11 adults have severe obesity. More

  • in

    Storms, air traffic control facility delay thousands of flights

    The Federal Aviation Administration briefly halted departures to the Washington D.C.-area, citing repairs needed at an air traffic control facility.
    Close to 10,000 flights were delayed on Sunday, mostly due to weather.

    A Southwest Boeing 737 airplane takes off into a smoke haze from Ronald Reagan Washington National Airport in Arlington, Virginia, June 8, 2023, as smoke from wildfires in Canada blankets the area.
    Saul Loeb | AFP | Getty Images

    More than 9,600 flights were delayed and 1,405 canceled on Sunday as thunderstorms snarled air travel in and out of some of the country’s busiest airports and the Federal Aviation Administration briefly halted departures to major airports serving Washington D.C., citing repairs to a power panel needed at an air traffic control facility.
    Shortly after 6 p.m. ET, the FAA issued ground stops for Baltimore/Washington International Thurgood Marshall Airport, Ronald Reagan Washington National Airport and Dulles International Airport, preventing aircraft from taking off for those destinations. It lifted the orders within an hour.

    “Departures to D.C.-area airports have resumed and repairs to the communications power panel are complete,” the FAA said in a statement. “During the repairs, a back-up system handled communications safely.” Delays at Washington Dulles were averaging around 90 minutes as of 7:15 p.m.
    Another 7,200 U.S. flights were delayed on Saturday. Throughout Sunday, weather caused delays at airports from Miami to Boston to Detroit.
    More than 500 flights to and from Newark Liberty International Airport were delayed. The airport is a major hub of United Airlines, which had more than 1,159 delayed mainline flights Sunday, network-wide, 40% according to FlightAware. American Airlines posted 1,258 delayed flights, 36% of its mainline schedule, Delta Air Lines had 1,221, or 34% of its schedule, and New York-based JetBlue Airways had 579 delays, or 55% of its planned schedule. More

  • in

    Stocks making the biggest premarket moves: Tesla, Moderna, Alphabet, PacWest and more

    A Tesla electric car is plugged into a recharging terminal at a Healthy Living Market store June 18, 2023 in South Burlington, Vermont. 
    Robert Nickelsberg | Getty Images

    Check out the companies making the biggest moves in premarket trading:
    Tesla — Shares dropped 1.9% after Goldman Sachs became the latest Wall Street bank to downgrade the electric vehicle maker to neutral from buy. Goldman cited the difficult pricing environment for electric vehicles, as well as the stock’s recent run up, for the call.

    Moderna — The drugmaker gained 2.5% following an upgrade by UBS to buy from neutral. The bank said the stock’s current valuation isn’t pricing in potential upside from other vaccines. UBS cut is price target to $191 from $221, which still implies 61% upside from Friday’s close.
    Lucid — The EV maker popped 12% after it announced a partnership with Aston Martin to supply powertrain and battery systems to the British luxury carmaker. Aston Martin will give Lucid a 3.7% stake in the company and cash payments totaling $232 million.
    Alphabet — The Google parent slid 1.4% after being downgraded by UBS to neutral from buy. The bank said the tech giant faces near-term revenue headwinds from new search competition and stiffer generative AI competition.
    Pfizer — Shares slipped 2.4% after the drugmaker announced it was discontinuing the clinical development of its experimental obesity and diabetes drug, lotiglipron. Studies had shown elevated liver enzymes, although no participants reported any symptoms or side effects.
    PacWest — The regional bank jumped nearly 6% following the announcement that Ares Management acquired $3.5 billion specialty finance portfolio from PacWest. The portfolio consists of high quality, senior secured, asset-backed loans.
    Carnival — Shares were up 1.9% ahead of the company’s earnings, expected before the bell. Cruise stocks have been soaring as the industry rebounds from the Covid pandemic. More

  • in

    Bitcoin is up 12% this month — even though barely anybody is trading it

    Bitcoin’s price has risen more than 12% since the beginning of June.
    Investors attributed the jump to news that BlackRock had filed for a spot bitcoin ETF.
    The more likely thing moving bitcoin, though, is large purchases by so-called bitcoin “whales” as liquidity remains low.
    This, analysts say, is causing big moves in the price of the world’s top digital currency.

    Andriy Onufriyenko | Moment | Getty Images

    Bitcoin has rallied sharply this month — but not for reasons you might think.
    The world’s largest digital currency has risen more than 12% since the beginning of June. On Wednesday, its price topped $30,000 to hit its highest level since April 14, according to Coin Metrics data.

    Market players have attributed the jump to the news that U.S. asset management giant BlackRock had filed for a spot bitcoin exchange-traded fund tracking the market price of the underlying asset.
    While that may be part of the reason, the outsized moved can be put down to another factor beyond the news flow surrounding large institutions taking steps to embrace bitcoin or other digital assets.

    Thin liquidity and big players

    Crypto “market depth” has been sitting at very low levels this year. Market depth refers to a market’s ability to absorb relatively large buy and sell orders. When market depth is low and big players put in orders to buy or sell digital coins, prices can move in a big way up or down, even if the orders are not that huge.
    Market depth is a measure of liquidity in a market.
    According to data firm Kaiko, bitcoin’s market depth has fallen 20% since the start of this year. Bitcoin has been one of the hardest-hit cryptocurrencies in terms of market depth, Kaiko said.

    The market depth of bitcoin at a 1% range from the mid price has fallen about 20% since the start of the year, according to data firm Kaiko.

    “Bitcoin’s recent surge in value has largely been driven by large trades within a less liquid market,” Jamie Sly, head of research at CCData, told CNBC via email.
    “Our analysis of market orders over 5 BTC reveals an aggressive surge in market buying, suggesting large players are seeking to gain exposure to digital assets.”
    “When combining large orders with thin books, the market is subject to more volatile movements,” Sly added.
    That lack of liquidity has in part been driven by the regulatory scrutiny of the crypto industry from U.S. authorities. The Securities and Exchange Commission has sued major exchanges such as Coinbase and Binance.
    Low liquidity, which has been a feature of the crypto market all year, is also partly behind bitcoin’s 80% year-to-date rally.

    Retail traders aren’t back — yet

    Another notable feature of the current crypto market is the low volumes being traded on exchanges.
    Daily trading volume in the cryptocurrency currently sits at around $24 billion, according to crypto data website CoinGecko.

    That’s down markedly from the more than $100 billion of overall trading volume in bitcoin during the peak of the 2021 crypto rally, when bitcoin rose close to an all-time high of nearly $69,000.
    Large crypto investors usually hope that an early surge in prices will be enough to tempt retail investors back into participating in the rally which ultimately boosts prices for bitcoin and other digital coins. But that hasn’t happened.
    “What is notable about this rally is that trade volumes overall are at multi-year lows, and we are only seeing a slight increase, which even then is far lower than levels we saw from January to March,” Clara Medalie, director of research at Kaiko, told CNBC.
    “I think trading volumes and price volatility are two of the most telling indicators of crypto market activity. Both volatility and volumes are at multi-year lows, and even a rapid increase in price is not enough to draw traders in.”

    ‘It’s not a market for ordinary clients’

    In the last bitcoin cycle, market momentum was largely driven by big, institutional names as investment banks from Morgan Stanley to Goldman Sachs set up trading desks to give their clients exposure to the digital currency.
    However, the market really started to break out only when retail traders started to take notice — in early 2021, people became tempted by the phenomenon that was NFTs, or nonfungible tokens, and other more speculative bets.
    Later that year, the cryptocurrency market experienced a seismic rally, with the price of bitcoin zooming to unprecedented levels. That was in tandem with surging trading volume, which climbed from $21.2 billion at the start of 2020 to $105.4 billion on Nov. 9, 2021, when bitcoin hits its all-time high, according to CoinGecko.
    Today, trading volume is nowhere near where it was at the height of the 2021 crypto boom.
    “Any bit of news, if it’s good, then the professional traders trade — otherwise, they’re not trading,” Carol Alexander, a professor of finance at the University of Sussex, told CNBC.
    “If a bit of good news like the bitcoin ETF comes, they fire the cannons upwards.”
    BlackRock’s ETF filing was followed by similar move from Invesco and WisdomTree, which also filed for their own respective bitcoin-related products.

    “Bitcoin and ether are both being manipulated in this way by the professional traders. They don’t trade most of the time, they wait until there’s a bit of good news,” Alexander said.
    “Then they’ll sell the top and you’ve got a sideways market.”
    Indeed, bitcoin has traded within a range this year, and attempts to burst significantly higher have been thwarted.
    Alexander thinks bitcoin is likely to trade within a range of between $25,000 and $30,000 for the remainder of the summer.
    She expects, however, that toward the end of the year, the cryptocurrency will climb toward $50,000, citing attempts from larger market players to prop up the market, with big purchases making outsized moves.
    “It’s not a market for ordinary clients. It’s really is not,” she warned.

    Has the market bottomed?

    Vijay Ayyar, vice president of international markets at the Indian crypto exchange CoinDCX, told CNBC he suspects the latest run-up in bitcoin’s price is being driven more by “long term institutional buyers.”
    Big funds and crypto-focused hedge funds are among the market participants driving the action, Ayyar added.
    “I don’t think this is as much of a retail push, since retail was quite flushed out during the recent pullback,” he said.
    Several crypto industry insiders have expressed hopes that the market is nearing a “bottoming” period where it can start to rise again.
    The recent price action echoes activity in 2018, when both bitcoin’s price and volumes were subdued for several months before beginning to rise again the following year.
    However, CCData’s Sly said it is “still too early to say whether the worst is over for bitcoin.”
    “The recent wave of interest from traditional financial institutions, like Blackrock, Citadel, and Fidelity instils a renewed optimism in the market,” he said.
    “Provided the wider macro environment and equity markets continue to be favorable, it is possible that bitcoin could maintain its current positive price trajectory.”
    WATCH: Can ethereum topple bitcoin as the crypto king? More

  • in

    Warner Bros. needs to stop copying Disney and let its superheroes fly solo

    The failure of “The Flash” should make Warner Bros. and DC Studios reconsider their newly adapted reboot plan.
    Marvel, owned by Disney, has cornered the market on shared superhero universes.
    DC has a better track record with movies and franchises focusing on a single hero.

    Ezra Miller stars as Barry Allen in Warner Bros.’ “The Flash.”
    Warner Bros. Discovery

    “The Flash” is a flop. “Black Adam” was a bust. And does anyone remember “Shazam: Fury of the Gods”?
    DC Studios needs more than a hero, it needs a new strategy – something different than even its recently established reboot plan.

    DC and its parent company, Warner Bros. Discovery, have Marvel Cinematic Universe envy. It’s easy to see why. The MCU’s movies, including ones that haven’t been released by Disney, have grossed about $30 billion worldwide since 2008. Warner Bros. Discovery CEO David Zaslav has directed DC Studios co-CEOs James Gunn and Peter Safran to create their own shared universe involving iconic characters like Batman and Superman.
    The problem is, Warner Bros. and DC are already working through the tail end of a previous – and failed – attempt to tie their characters together through multiple films and shows. At the movies, DC’s Justice League just can’t measure up against Marvel’s Avengers.
    The likely answer to Warner Bros. and DC’s issues is right in front of them, though: Character-specific franchises that adhere to one filmmaker’s vision, not a TV-style writers room. Basically, let your heroes fly solo.
    It’s worked for DC properties before, even recently.
    Read more: Legacy media companies enter dark times as failures mount

    Christopher Nolan’s Batman trilogy, which wrapped in 2012, was a well-reviewed box office juggernaut. And even though they were both connected to the prior attempt at creating a DC movie universe, 2017’s “Wonder Woman” and 2018’s “Aquaman” focused mainly on their title characters and racked up big bucks and accolades in the process.
    To put an even finer point on it, look no further than the financial and critical success of Todd Phillips’ “Joker” and Matt Reeves’ “The Batman.” Neither movie is connected to an extended universe.
    “Joker,” released in 2019, grossed more than $1 billion worldwide despite being rated R, while racking up a best actor Oscar for star Joaquin Phoenix. Last year’s “The Batman,” starring Robert Pattinson as an early-career Caped Crusader, garnered around $750 million globally. Sequels to both movies are in the works.
    But so is “Batman: The Brave and the Bold,” from “Flash” director Andy Muschietti. It will not star Pattinson and will instead serve as “the introduction of the DCU Batman,” according to Gunn. How many different Batmen does an already-superhero-saturated moviegoing audience need? Especially after “The Flash,” which featured four different Dark Knights from previous movies and shows.

    Fun vs. homework

    Marvel Studios’ “Ant-Man and the Wasp: Quantumania.”

    Comic books were once a refuge from homework. Now, to keep up with everything going on in Disney’s MCU and Sony’s Spider-Verse, which is also connected to the MCU, you need to have watched pretty much everything that came before to get up to speed. That’s dozens of movies and shows, going back to the original Robert Downey Jr. “Iron Man.”
    “The Flash,” meanwhile, might be the most intense comic book movie pop quiz, even though DC’s cinematic universe has been all over the place. It’s jam-packed with cameos (some real, some CGI-generated) from past DC movies and shows, going all the way back to George Reeves’ black-and-white Superman.
    But in order to understand all the gags, you have to be really into this stuff. Unless you’re a big fan of “Clerks” director Kevin Smith – big enough of a fan to have watched his standup specials, that is – a “Flash” sequence involving a Nicolas Cage version of Superman fighting a giant spider might be lost on you. The movie’s punchline, involving George Clooney returning to the role of Bruce Wayne 26 years after the badly received “Batman and Robin,” is clearly geared toward Gen-Xers and older Millennials, not today’s younger audiences.
    Even the MCU model has tripped up at times. Disney CEO Bob Iger himself has suggested that the studio was going to the well too often with certain characters, after the fourth Thor film and third Ant-Man installment underwhelmed at the box office. That should be another warning sign for DC Studios.
    For his part, DC’s Gunn recently acknowledged that there are “too many” superhero movies and shows. If anyone can come up with a creative way to change course, it’s him.
    After working with schlock factory Troma Films early on, Gunn built a sturdy Hollywood career as a writer and director, alternating between R-rated flicks like “Slither” and stuff for general audiences, like his Guardians of the Galaxy movies for Marvel and Disney. The third entry in that series snapped the MCU out of its mini funk. It’s so far the second-highest-grossing movie of 2023, behind Universal’s “The Super Mario Bros. Movie.”
    And he already has a couple DC works on his resume: the 2020 movie “The Suicide Squad” and its 2022 companion series, “Peacemaker,” both of which won wide acclaim.
    Gunn is writing and directing “Superman: Legacy,” due in 2025. It’s intended to usher in the new DC shared universe. But there’s still time for him to reconsider his approach and let the Man of Steel – and all the other DC heroes – be super on their own.
    Disclosure: NBCUniversal is the parent company of Universal and CNBC. More